LadRx (LSE:0I5R) - Stock Price, News & Analysis

0I5R Stock Overview

A biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. More details

0I5R fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 94.7% below our estimate of its fair value

Became profitable this year

Risk Analysis

Does not have a meaningful market cap ($926K)

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Shareholders have been diluted in the past year

LadRx Corporation Competitors

Bioventix

AIM:BVXP

UK£193.1m

NAVCO Pharmaceuticals

TSXV:NAV

CA$856.0k

Hindustan Bio Sciences

BSE:532041

₹102.4m

Epigenomics

DB:ECX

€1.2m

Price History & Performance

Summary of all time highs, changes and price drops for LadRx
Historical stock prices
Current Share Price	US$1.00
52 Week High	US$17.70
52 Week Low	US$1.00
Beta	1.62
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.69%
5 Year Change	n/a
Change since IPO	-99.51%

Recent updates

Shareholder Returns

	0I5R	GB Biotechs	GB Market
7D	0%	4.1%	1.7%
1Y	n/a	-14.2%	9.0%

Return vs Industry: Insufficient data to determine how 0I5R performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0I5R performed against the UK Market.

Price Volatility

Is 0I5R's price volatile compared to industry and market?
0I5R volatility
0I5R Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0I5R has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0I5R's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1985	3	Stephen Snowdy	www.ladrxcorp.com

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.

LadRx Corporation Fundamentals Summary

How do LadRx's earnings and revenue compare to its market cap?
0I5R fundamental statistics
Market cap	US$925.82k
Earnings (TTM)	US$176.65k
Revenue (TTM)	n/a

5.6x

P/E Ratio

0.0x

P/S Ratio

Is 0I5R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0I5R income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	-US$176.65k
Earnings	US$176.65k

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.36
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0I5R perform over the long term?

See historical performance and comparison

LadRx LSE:0I5R Stock Report